The Court found that Ariosa’s Harmony non-invasive prenatal test infringed EP 1 524 321 and that the patent claims were valid. The patent is directed to the size selection of extracellular DNA in maternal plasma samples. Size selection boosts the fetal fraction, leading to fewer test samples being rejected for low fetal fraction.
“We are pleased that the
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
Karen Birmingham (Europe)